scispace - formally typeset
Open AccessJournal ArticleDOI

Co-infection of SARS-CoV-2 with other respiratory pathogens in patients with liver disease

Reads0
Chats0
TLDR
Ground glass opacity (GGO) with consolidation was found to be the most common radiological finding among SARS-CoV-2 positive co-infected patients, as compared to only GGO among Sars-Cov-2 mono- Infected patients.
Abstract
Respiratory illness caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first documented in Wuhan, China, in December 2019, followed by its rapid spread across the globe. Accumulating evidence has demonstrated viral/bacterial co-infection in the respiratory tract could modulate disease severity and its outcome in COVID-19 infection. In this retrospective study, 300 chronic liver disease patients with radiologically confirmed lower respiratory tract infection were enrolled from September 2020 to December 2021. In all of them, along with SARS-CoV-2, other respiratory viral/bacterial pathogens were studied. In total, 23.7 % (n=71) patients were positive for SARS-CoV-2. Among the positive patients, 23.9 % (n=17) had co-infection with other respiratory pathogens, bacterial co-infections being dominant. The SARS-CoV-2 negative cohort had 39.7  % positivity (n=91) for other respiratory pathogens, the most common being those of the rhinovirus/enterovirus family. Ground glass opacity (GGO) with consolidation was found to be the most common radiological finding among SARS-CoV-2 positive co-infected patients, as compared to only GGO among SARS-CoV-2 mono-infected patients. Accurate diagnosis of co-infections, especially during pandemics including COVID-19, can ameliorate the treatment and management of suspected cases.

read more

References
More filters
Journal ArticleDOI

Characteristics of SARS-CoV-2 and COVID-19

TL;DR: The basic virology of SARS-CoV-2 is described, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses.
Journal ArticleDOI

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.

TL;DR: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19, which can aggravate the damage to the heart.
Journal ArticleDOI

The COVID-19 Cytokine Storm; What We Know So Far.

TL;DR: Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality.
Journal ArticleDOI

Middle East respiratory syndrome.

TL;DR: The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012.
Journal ArticleDOI

Middle East Respiratory Syndrome

TL;DR: No specifi c drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities, however, the virus could mutate to have increased interhuman transmissibility, increasing its pandemic potential.
Related Papers (5)